Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec”
Insider Monkey – Free Hedge Fund and Insider Trading Data (Syeda Seirut Javed)Design Therapeutics, Inc. (NASDAQ:DSGN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. A caller asked for Cramer’s thoughts on the company, and here’s what he had to say:
Pure spec, pure spec. Understand, you can lose everything, or you can double on that one. I don’t know which it’s going to be. That’s the problem.
A stock market graph. Photo by energepic.com
Design Therapeutics, Inc. (NASDAQ:DSGN) is a clinical-stage biopharmaceutical company that develops small-molecule drugs to treat inherited genetic diseases caused by nucleotide repeat expansion. The company uses its proprietary platform, GeneTAC, to create potential treatments for conditions such as Friedreich’s Ataxia, Huntington’s Disease, and other progressive neuromuscular and neurodegenerative disorders.
[im-yf-promo]
While we acknowledge the potential of DSGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
[/im-yf-promo]
While we acknowledge the risk and potential of DSGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DSGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Generated by RSStT. The copyright belongs to the original author.